Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.

Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN.

Oncotarget. 2014 Jul 30;5(14):5637-50.

PMID:
25026298
[PubMed - in process]
Free Article
2.

Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.

Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P, Bhalla KN.

Mol Cancer Ther. 2012 Apr;11(4):973-83. doi: 10.1158/1535-7163.MCT-11-0979. Epub 2012 Feb 24.

PMID:
22367781
[PubMed - indexed for MEDLINE]
Free Article
3.

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J.

Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22.

PMID:
22915752
[PubMed - indexed for MEDLINE]
4.

TGFbeta Induces 'BRCAness' and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA Repair Genes.

Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang SE.

Mol Cancer Res. 2014 Aug 7. pii: molcanres.0201.2014. [Epub ahead of print]

PMID:
25103497
[PubMed - as supplied by publisher]
5.

Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.

Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL.

Breast Cancer Res Treat. 2012 Jul;134(2):649-59. doi: 10.1007/s10549-012-2106-5. Epub 2012 Jun 8.

PMID:
22678161
[PubMed - indexed for MEDLINE]
6.

Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.

Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK.

J Nucl Med. 2013 Jun;54(6):913-21. doi: 10.2967/jnumed.112.111534. Epub 2013 Apr 5.

PMID:
23564760
[PubMed - indexed for MEDLINE]
Free Article
7.

Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.

Comen EA, Robson M.

Cancer J. 2010 Jan-Feb;16(1):48-52. doi: 10.1097/PPO.0b013e3181cf01eb. Review.

PMID:
20164690
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Clark CC, Weitzel JN, O'Connor TR.

Mol Cancer Ther. 2012 Sep;11(9):1948-58. doi: 10.1158/1535-7163.MCT-11-0597. Epub 2012 Jul 9.

PMID:
22778154
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.

Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.

Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

PMID:
22357256
[PubMed - indexed for MEDLINE]
Free Article
10.

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.

Hastak K, Alli E, Ford JM.

Cancer Res. 2010 Oct 15;70(20):7970-80. doi: 10.1158/0008-5472.CAN-09-4521. Epub 2010 Aug 26.

PMID:
20798217
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. doi: 10.1073/pnas.0806092105. Epub 2008 Oct 29.

PMID:
18971340
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer.

Ratanaphan A.

Int J Mol Sci. 2012 Nov 14;13(11):14898-916. doi: 10.3390/ijms131114898.

PMID:
23203101
[PubMed - in process]
Free PMC Article
13.

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, Duggan P, Tassone P, Mansoor A, Stewart DA, Lonial S, Boise LH, Bahlis NJ.

Blood. 2011 Dec 8;118(24):6368-79. doi: 10.1182/blood-2011-06-363911. Epub 2011 Sep 13.

PMID:
21917757
[PubMed - indexed for MEDLINE]
Free Article
14.

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE.

J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.

PMID:
20100965
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.

Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K.

Clin Cancer Res. 2007 Aug 15;13(16):4882-90.

PMID:
17699868
[PubMed - indexed for MEDLINE]
Free Article
16.

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.

Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA.

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13650-5. doi: 10.1073/pnas.1203326109. Epub 2012 Aug 6.

PMID:
22869732
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

Davidson D, Wang Y, Aloyz R, Panasci L.

Invest New Drugs. 2013 Apr;31(2):461-8. doi: 10.1007/s10637-012-9886-7. Epub 2012 Oct 9.

PMID:
23054213
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.

Fiskus W, Hembruff SL, Rao R, Sharma P, Balusu R, Venkannagari S, Smith JE, Peth K, Peiper SC, Bhalla KN.

Breast Cancer Res Treat. 2012 Sep;135(2):433-44. doi: 10.1007/s10549-012-2171-9. Epub 2012 Jul 24.

PMID:
22825030
[PubMed - indexed for MEDLINE]
19.

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.

Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA.

J Pathol. 2011 Aug;224(4):564-74. doi: 10.1002/path.2925. Epub 2011 Jun 27.

PMID:
21706479
[PubMed - indexed for MEDLINE]
20.

Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors.

Park Y, Moriyama A, Kitahara T, Yoshida Y, Urita T, Kato R.

Anticancer Agents Med Chem. 2012 Jul;12(6):672-7. Review.

PMID:
22263793
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk